More data needed to determine best use of dornase-alfa in cystic fibrosis

@article{Prescott1996MoreDN,
  title={More data needed to determine best use of dornase-alfa in cystic fibrosis},
  author={Lawrence Prescott},
  journal={Inpharma Weekly},
  year={1996},
  volume={1041},
  pages={3}
}
Although there is general agreement that dornase-alfa [Pulmozyme®; Genetech] is beneficial as a treatment for cystic fibrosis, leading respiratory specialists have called for further confirmatory studies of the drug’s efficacy. Additional data that clearly demonstrate the agent’s positive effects are required to justify the high cost of this treatment. These viewpoints were aired during a debate on the pros and cons of dornase-alfa therapy at the International Conference of the American… CONTINUE READING

Topics from this paper.